Trial reportClinical ophthalmology (Auckland, N.Z.)2022
Canaloplasty and Trabeculotomy Combined with Phacoemulsification for Glaucoma: 12-Month Results of the GEMINI Study.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic burden of the OMNIEuropean journal of ophthalmology · 2026Pooled it
- Safety and Efficacy of STREAMLINE Canaloplasty with Phacoemulsification in Hispanic Adults with Open-Angle Glaucoma: 12-Month Outcomes.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Outcomes of phacoemulsification combined with ab interno trabeculotomy: stratified by incision extent, glaucoma severity, and baseline number of medications.Eye (London, England) · 2026Article
- Viscodilation of Schlemm canal and trabeculotomy for reducing intraocular pressure and medication use in pseudophakic eyes.Journal of cataract and refractive surgery · 2026Article
- Ab Interno Minimally Invasive Glaucoma Surgery Effectiveness in Black Patients: An IRIS Registry Study.Journal of glaucoma · 2026Observational
- Real-World Outcomes of Combined Goniotomy and Canaloplasty Using the Streamline Surgical System.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Ab Interno Goniotomy/Goniectomy TechniquesTurkish journal of ophthalmology · 2025Review
- Retrospective Study of 2-year Clinical Outcomes of Combination Ab-Interno Canaloplasty and a Microstent Compared to Ab-Interno Canaloplasty in Cataract Surgery Patients.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Performance and Safety of Minimally Invasive Nasal Trabeculostomy (MINT™) in Open-Angle Glaucoma: A 12-month Open-Label Study on Patients with No Other Glaucoma Surgeries.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- One year clinical outcomes with a novel canaloplasty device in mild to severe open angle glaucoma.International journal of ophthalmology · 2025Article
- Revolution in glaucoma treatment: a review elucidating canaloplasty and gonioscopy-assisted transluminal trabeculotomy as modern surgical alternatives.Frontiers in medicine · 2025Review
- Article
- Comparison of Superior versus Inferior Canaloplasty and Trabeculotomy Using the OMNI Surgical System.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Ab Interno Canaloplasty and Trabeculotomy Outcomes for Mild, Moderate, and Advanced Open-Angle Glaucoma: A ROMEO Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Efficacy and Safety of Ab-Interno Canaloplasty in Post-Keratoplasty Patients: 3-Year Results.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Prospective Study of Canaloplasty and Trabeculotomy Performed by Trainees.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- IOP-lowering and drug-sparing effects of trabectome surgery with or without cyclodialysis ab interno.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- First-Generation iStent Bypass Implantation versus ab Externo Canaloplasty Combined with Phacoemulsification in Patients with Primary Open Angle Glaucoma-12-Month Follow-Up.Journal of clinical medicine · 2023Article
- Canaloplasty and trabeculotomy with the OMNIInternational ophthalmology · 2023Article
- [Minimally invasive glaucoma surgery-Comparison of angle based procedures].Die Ophthalmologie · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report 12-month efficacy outcomes of 360° canaloplasty and 180° trabeculotomy using the OMNI surgical system in combination with phacoemulsification in patients with mild-moderate open-angle glaucoma (OAG) and visually significant cataract. Setting: Fifteen multi-subspecialty ophthalmology practices and surgery centers located in 14 US states. Design: Prospective, multicenter, IRB approved study of patients treated with canaloplasty (360°) and trabeculotomy (180°). Eligible patients had cataract and mild-moderate OAG with intraocular pressure (IOP) ≤33 mmHg on 1 to 4 hypotensive medications. Unmedicated post-washout mean diurnal IOP (DIOP) ≥21 and ≤36 mmHg. Methods: Medication washout preoperatively and prior to month 12 DIOP. Effectiveness outcomes were IOP and IOP lowering medication use. Safety outcomes included adverse events and secondary surgical interventions (SSIs). Evaluations at 1, 3, 6, and 12 months. Results: A total of 149 subjects underwent surgery and 120 were included in the final effectiveness analysis. Mean (standard deviation) unmedicated diurnal IOP was reduced from 23.8 (3.1) mmHg at baseline to 15.6 (4.0) at month 12 (-35%) and medications (before washout) were reduced from 1.8 (0.9) at baseline to 0.4 (0.9) at month 12 (-80%). At month 12, 84.2% of eyes achieved IOP reductions >20% from baseline, 80% of eyes were medication-free, and 76% of eyes achieved IOP between 6-18 mmHg inclusive. Adverse events were uncommon. Most were mild and self-limited including transient hyphema (9 of 149; 6%) and transient IOP elevations (3 of 149; 2.0%). No eyes required SSIs or experienced loss of VA that was attributable to the device or procedure. Conclusion: Canaloplasty and trabeculotomy performed with the OMNI surgical system at the time of phacoemulsification significantly reduces unmedicated mean diurnal IOP and medication use 12 months postoperatively, with an excellent safety profile. This procedure should be considered for eyes with mild-moderate OAG to reduce IOP, medication burden, or both.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.